After 24 weeks of Dupilumab treatment, the analyzed patients experienced remarkable improvement in SNOT-22, NPS and NRS parameters; while resulted in a significant reduction of peripheral eosinophilia and in the enhancement of total IgE (Figure 4). This evidence concerns the gene IGHE and Increased total eosinophil count.